For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA3488Ua&default-theme=true
RNS Number : 3488U Advanced Medical Solutions Grp PLC 01 August 2022
1 August 2022
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Directorate Change
Liz Shanahan Appointed as an Independent Non-Executive Director
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, is pleased to
announce that, as the next step in its communicated plan to refresh the
Non-Executive Directors on the Board, Liz Shanahan will be appointed as an
Independent Non-Executive Director with immediate effect.
Liz is a life sciences entrepreneur with extensive experience advising leading
global pharmaceutical and healthcare organisations on their communications.
She is currently a Non-Executive Director of Inspiration Healthcare Group plc
and Celadon Pharmaceuticals plc (previously Summerway Capital plc), both of
which are AIM-listed. Most recently, she was a Non-Executive Director of UDG
Healthcare plc, a company that was listed on the London Stock Exchange and a
constituent of the FTSE 250 up until its £2.8 billion takeover in August
2021.
Until 2014, she was Global Head of Healthcare & Lifesciences at the
NYSE-listed management consultancy, FTI Consulting Inc., which in 2007
acquired the communications business Santé Communications, founded by Liz in
1995. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster
Foundation Trust Hospital in London and a member of the organisation's
Innovations Advisory Board. Alongside her Board appointments she is a business
advisor and Executive coach.
Peter Allen, Chairman of AMS, said: "I am very pleased to welcome Liz to the
Board of AMS, who brings with her significant experience in healthcare
organisations, as well as specialist skills in communication and Executive
coaching. She will be an extremely valuable addition to our Board."
Liz Shanahan commented: "I have been watching AMS's progress closely during my
career and am very excited to be joining the Board of such a high-quality
Company."
Liz will immediately join the Audit, Nomination and Remuneration Committees
and will be responsible for Workforce Engagement in line with the UK Corporate
Governance Code requirements. The composition of each of the Board Committees
from 1 August 2022 is therefore confirmed as follows:
Board Committee Membership
Audit Committee Grahame Cook (Chairman)
Douglas Le Fort
Liz Shanahan
Nomination Committee Peter Allen (Chairman)
Grahame Cook
Douglas Le Fort
Chris Meredith
Liz Shanahan
Remuneration Committee Douglas Le Fort (Chairman)
Peter Allen
Grahame Cook
Liz Shanahan
The following information is disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies:
Elizabeth Ann Shanahan (age 57) holds or has held Directorships and
partnerships in the five years preceding her appointment at AMS as follows:
Current Directorships Previous Directorships
Celadon Pharmaceuticals plc Chelsea & Westminster Hospital NHS Foundation Trust
(previously Summerway Capital plc)
Inspiration Healthcare Group plc UDG Healthcare plc
Akusus Holdings Ltd Connected Tech Group Ltd (previously Captive
Health Limited)
CWPlus (Director and Trustee) Kingdom Clinics Limited
Onetouchtelecare Limited Kingdom R&D Ltd
Kingdom Therapeutics Limited Kingdom Laboratories Ltd
Sante Healthcare Consulting Ltd
No further information in connection with her appointment is required to be
disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
-End -
For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Matthew Cole AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
Daniel Adams / Gary Clarence
HSBC Bank PLC (Broker) Tel: +44 (0) 20 7991 8888
Sam McLennan / Joe Weaving / Stephanie Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor of
minimally invasive surgical devices based in Austria.
AMS's products, manufactured in the UK, Germany, France, Israel, the
Netherlands, and the Czech Republic, are sold globally via a network of
multinational or regional partners and distributors, as well as via AMS's own
direct sales forces in the UK, Germany, the Czech Republic and Russia. The
Group has R&D innovation hubs in the UK, Germany, France and Israel.
Established in 1991, the Group has more than 700 employees. For more
information, please see www.admedsol.com (http://www.admedsol.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAEANXFDESAEFA